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EVALUATING THE DELAY PRIOR TO PRIMARY CARE PRESENTATION IN LUNG 
CANCER PATIENTS  
ABSTRACT
Background: Little is known about “within-patient delay”, time from first symptom of lung 
cancer to contacting primary care.
Aim: Primary outcomes were length of within-patient delay and the proportion of total 
delay it represents. Secondary outcomes were factors causing delay and survival. 
Design and Setting: Newly diagnosed lung cancer oncology patients at two hospitals in 
Norfolk.
Method: Patients completed questionnaires regarding onset of symptoms, whether they 
had delayed, and their reasons. GPs completed correlating questionnaires. Pathway times 
and other data were extracted from cancer registry and hospital records and outcomes 
obtained prospectively. Factors causing delay were compared using ratios of geometric 
means. 
Results: 
In 379 patients, mean within-patient delay and pre-secondary care delay were 188.6 and 
241 days (61.4% and 78.5% of total delay respectively). 
38.8% patients felt they had delayed. Patient-related causes of delay were denial (ratio of 
means (ROM) 4.36, p=0.002, 95% CIs 1.71-11.1), anxiety (3.36, 0.026, 1.16-9.76), non-
























These symptoms were associated with delay: finger swelling/discomfort (ROM=2.72, 
p=0.009, CIs 1.29-5.74), cough (2.53, <0.001, 1.52-4.19), weight loss (2.41, <0.001, 1.49-3.88), 
weakness (2.35, 0.001, 1.45-3.83), dyspnoea (2.30,  0.001, 1.40-3.80), voice change (1.90,  0.010, 
1.17-3.10)  and sputum (1.66, 0.039, 1.03-2.67), respectively, also having more than five 
symptoms (compared to 1-3) (3.69, <0.001, 2.05-6.64).  
No overall relation between within-patient delay and survival was seen.
Conclusion: Using smoking registers, awareness literature and self-care manuals, primary 
care staff could liaise with ever-smokers regarding their symptoms, to ensure early referral 
to secondary care.
HOW THIS FITS IN
Lung cancer patients present late, so there is much interest in reducing delay to treatment.
We studied the major phases of delay in lung cancer patients’ pathways, and asked patients 
who delayed the reasons for their delay.
The delay before the patient first contacts primary care is over sixty percent of total delay to 
treatment and its commonest cause is non-recognition of the symptoms.
Public health measures and primary care networks need to ensure that at-risk people know 























liaise with them regarding their symptoms to encourage early referral to CT or secondary 
care.       
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Causes of delay                                 























EVALUATING THE DELAY PRIOR TO PRIMARY CARE PRESENTATION IN LUNG 
CANCER PATIENTS  
INTRODUCTION
Lung cancer is the commonest cause of cancer death worldwide1. Seventy percent of UK 
patients present in advanced stage2, when curative surgery is not possible. Our overall five-
year survival of 10%3 is low by international standards4. Recent approaches to improving 
results include: increasing awareness, screening, streamlining secondary care and earlier 
identification in primary care 5. 
Improved awareness campaigns have shown short-term benefits6-8, but are hard to sustain. 
Low-dose CT screening can improve mortality9,10, but cost-effectiveness11 and 
implementation are problematic12,5.  Despite targets in secondary care13, results remain 
poor. Interventions which target high-risk groups can improve respiratory consultation 
rates14,15. 
Another approach is to focus on avoidable prolongation in the time from presentation to 
treatment (delay) and its causes. Cohort studies have used questionnaire models16,17, case-
notes review18-19 and interview20-21. The causes of delay include limited symptom awareness, 
anxiety, denial and being too busy22-25.  Smokers are less likely than non-smokers to seek 
























Delay worsens prognosis in patients treated with curative intent29,30. However, in lung 
cancer patients as a whole, the effect of delay is less clear, some authors showing a longer 
time from presentation to treatment associated with better survival31,32, others with 
worse18. Possible reasons are that presenting symptoms can be non-specific17, with 
uncertainty as to when the disease began, or that studies concentrating on major symptoms 
only16,31 may miss earlier ones.    
Audits of delay often start from the first contact with primary care33 but ignore the earlier 
time from the first symptom. This “within-patient delay” 34 may be prolonged20,27,35, and 
contribute to poor outcomes. No study has compared all phases to treatment 
quantitatively. 
There is therefore a need to quantify the length of within-patient delay, the proportion of 
delay it represents, the principal factors causing delay, and how all these affect survival.
METHODS
Design, Setting and Governance: This cohort study involved questionnaires, tertiary care 
and cancer registry data, with outcomes obtained prospectively. Patients with a recent 
diagnosis of lung cancer were recruited from thoracic oncology clinics at the Norfolk and 
Norwich and James Paget University Hospitals between April 2008 and June 2012. The study 























Patient recruitment: All lung cancer patients were given an information pack and consent 
form with a freepost envelope, together with the patient questionnaire (PQ), by the doctor 
or research nurse at clinic. Patients were eligible if they provided written informed consent 
and were able to complete the 27-question questionnaire. 
Data collection:
Patient data: The patient questionnaire asked about symptoms and events which led to the 
diagnosis, with dates of onset. This was in two sections. 
The first section concerned symptoms and began: “What was the first symptom which you 
feel was the beginning of this illness?” asking for the date or time in weeks since this 
developed. Exact dates were used if given, but where the patient gave only the month, the 
first of the month was used36. Then followed nineteen questions on specific symptoms, 
asking whether they had suffered these or not and, if so, the starting date or time in weeks. 
These symptoms were: dyspnoea, cough, sputum, purulence, haemoptysis, wheeze, chest 
pain, weight loss, anorexia, weakness, taste change, dry mouth, pyrexia, voice 
weakness/hoarseness (defined as voice change), finger swelling/discomfort (surrogate for 
clubbing), metastatic symptoms, dysphagia, neck lumps and neck swelling. The 
questionnaire was self-administered and employed patient-friendly terms throughout. For 
example, rather than “dysphagia”, it asked “have you had any trouble swallowing?” Finally it 
asked about any other symptoms which they felt were part of the illness, with dates. This 
type of questionnaire, asking whether the patient suffered a symptom and, if so, date of 























The second section asked whether they delayed in contacting their doctor and, if so, for 
what reason, when they saw him/her, the response, and how many times they saw him/her 
before being referred for a CXR or to secondary care. The questionnaire was reviewed early 
in the study, to ensure it was well-understood and being completed satisfactorily, and 
continued, following correction of one spelling error. 
Primary care data: GPs received a letter explaining the purposes of the study. This also 
asked them to complete a short questionnaire, asking the date first consulted about the 
symptoms which led to the lung cancer diagnosis, how many further consultations took 
place, dates of all consultations and the date of referral to secondary care or for the CXR 
which led to secondary care referral.
Outcomes: Primary outcomes were the length of within-patient delay and the proportion of 
total delay which it represents. Secondary outcomes were factors causing delay, and the 
relation between these and survival.
Data handling and additional data retrieved: A research nurse recorded all questionnaire 
responses on a datasheet. Study researchers also retrieved data from hospital records and 
cancer registry, including: demographic patient data, age at diagnosis, date of diagnosis, 
postcode, index of multiple deprivation (IMD), tumour stage, site and histology, treatment 
intent (radical/palliative), smoking data (dates of starting and quitting, pack-years), asbestos 
exposure and patient status at close of study. Outcomes data were captured in October 
2015, providing a minimum of 39 months follow-up. Dates needed to identify the phases in 























Symptoms consistent with known metastases, such as bone pain with a corresponding scan, 
were defined as “metastatic symptoms”, and analysed along with other symptoms18. Non-
specific symptoms such as abdominal pain were excluded from analysis.
Tumour, node and metastasis (TNM) and stage-grouping followed the International Union 
against Cancer and American Joint Committee on Cancer 7th edition38. All questionnaires, 
demographic data and key pathway dates were carefully checked.  Following compilation of 
questionnaire data, the datasheet was anonymised. Date of diagnosis was defined as the 
date of biopsy which gave the histological diagnosis or, where there was no histology, date 
of radiological procedure which gave the diagnosis38. Survival was measured from date of 
diagnosis until death, or the time of assessment, if still alive. Our approaches to data 
collection, analysis and reporting are consistent with the Aarhus statement on the design 
and reporting of studies on early cancer diagnosis39.   
Pathway phases: Five validated patient pathway phases, modified from Olesen et al20, were 
defined as in Supplementary Table 1. This also shows the source of data e g whether from 
patient or GP questionnaire.  Start of within-patient delay was taken as the earliest date 
given in response to all relevant questions. 
The PQ and GPQ both recorded the date the patient first saw their GP, but in case of 
discrepancy, the GPQ date was used. Similarly the GPQ and cancer registry both recorded 
the date of referral to secondary care. Discrepancy was rare but, if this occurred, the cancer 
registry was used in preference. 
Analysis: Dividing patients into two groups based around median delay, it was calculated 























between groups, with a hazard ratio of 1.337. Therefore a sample size of 386 participants 
was chosen. This also permitted the use of up to 38 variables in the regression analysis40. 
Survival within phases was also studied using subgroups according to length of delay. 
Descriptive analyses were reported on all measured variables for the whole group. These 
included demographic, patient, tumour and symptom details, additional data as above and 
lengths of pathway phases (Supplementary Table 1). 
Due to the non-normal distribution, the model was based on the logarithm of delay41. In 
order to aid interpretation, the resulting regression coefficients were exponentiated to give 
ratios of geometric means42. For analysis of within-patient delay and survival, all variables 
above were included, also whether patients delayed and for what reason, each symptom 
and the number of symptoms patients had. The final phase was not included in survival 
analysis since survival was measured from date of diagnosis.
These variables were assessed univariately using a regression model.  All analyses were 
undertaken using STATA 14.1/SE (Texas, USA).
RESULTS
544 patients were recruited in order for 392 patient questionnaires to be returned. Thirteen 
were excluded - 2 non-lung primaries (thyroid and colorectal) and 11 questionnaires 
inadequately completed - leaving 379 for analysis. Of these, GP questionnaires were 























Supplementary Table 2 shows demographic, smoking and tumour data,, treatment intent, 
the number (%) of patients who delayed overall,  commonest reasons for delaying,  
numbers (%s) of patients with various numbers of symptoms and the current status.
Of the 363 (95.8%) patients answering the first question and also completing details on the 
symptoms section of the questionnaire, 163 (37.7%) mentioned symptoms which started 
before the date they gave as the beginning of the illness.
Mean within-patient delay was 188.6 days, 61.4% of total delay (median 84 days). Mean 
pre-secondary care delay was 241 days, 78.5% of total delay (median 142 days) 
(Supplementary Table 3).
Supplementary Table 4 shows how smoking, delaying, symptoms and number of symptoms 
all affected the length of delay in patients contacting primary care.
Age, gender, IMD, stage, histology, tumour site and asbestos exposure were not found to 
influence within-patient delay.
As Supplementary Table 5 shows, survival was not altered by lengths of pathway phases, 
subgroups of within-patient delay, patients believing that they delayed, nor delay from 
various known causes. Stage and treatment intent strongly affected survival. Age, gender, 
IMD and asbestos exposure did not affect survival.
Supplementary Table 6 shows, in a post-hoc analysis, how within-patient delay affected 

























Within-patient delay, at 84 days median, is much the longest phase, over 60% of total mean 
delay. Likewise, pre-secondary care delay, median 142 days, is almost 80%. Current smokers 
delay longer. Denial, anxiety and failure to recognise the symptoms are the most significant 
factors causing delay. 
Seven symptoms are individually associated with longer within-patient delay. Also, the 
greater the number of symptoms a patient has, the longer is their delay. However, no 
overall relation was seen between within-patient delay and survival, nor between any 
pathway phase and survival.
Strengths and limitations
Strengths: We accurately measured the time of the first symptom, by asking closed 
questions on a large number of lung cancer-related symptoms, thereby accurately 
measuring within-patient delay. We compared this length with that of later pathway phases. 
Factors causing this delay have been identified, with their frequency, their effect on delay 
and survival. We studied the relation between number of symptoms and delay. Finally, we 
have long-term survival data. 
The seven symptoms associated with delay are intuitive. Dyspnoea, cough and sputum are 
all common to benign disease17, clubbing may not concern patients, weight loss and 
weakness may not initially cause anxiety and patients with voice weakness/loss from lung 
cancer are often seen at ENT before being referred to respiratory clinics, so delay can be 























Limitations: A limitation is that all symptoms data and dates of medical contact were 
obtained retrospectively by questionnaires, with the possibility of recall bias. However, 
symptom recognition from a checklist of symptoms (as on the questionnaire) has been 
shown to improve recall43. Also a breast cancer study, which explored reasons for delay, 
achieved meaningful results despite patients being approached 3 months to 5 years after 
diagnosis44. In any case, we cross-referenced with primary care electronic records and 
secondary care databases39, and the outcomes data were obtained prospectively.  
Since our patients were recruited from Oncology, we did not capture all incident cases. Had 
we included all patients receiving curative surgery, the relationship between within-patient 
delay and outcome might have been stronger, since early-stage patients are likely to have 
had less delay. However, our percentages of patients in stage III-IV (86.3%) are similar to 
those of national data in England and Wales (72-76%)2. We therefore believe these findings 
apply to unselected lung cancer patients presenting in primary care.
In completing the questionnaire, ove  a third of patients mentioned symptoms starting 
before the date they gave as the beginning of the illness (see Results). They therefore 
experienced symptoms before realising that they were ill and needing help. This illustrates 
the difficulty patents have in recognising symptoms. Other lung cancer researchers have 
asked separately about the start of the illness and dates of symptoms17.
Much of the data is over five years old. The delay in reporting relates to our requiring long-























has not changed significantly, and outcomes remain poor despite government targets13, 
reducing within-patient delay is now an even more important aim.
Comparison with existing literature
Our results are consistent with an interview study which found 99 days median within-
patient delay35. The long delay before primary care is clinically important in view of 
published volume doubling times of 98 days in lung cancer45. A case-control study found the 
incidence of symptoms was higher in cases than controls from as long as two years before 
diagnosis46.  
Our within-patient delay combines “appraisal delay” (time to recognise one needs 
healthcare help) and “help-seeking delay” (time to be seen)47. Since only three patients 
(0.8%) reported difficulty in making a GP appointment as a cause of delay (Table 2), we 
believe this is reasonable. 
Our study is the first to attempt accurately to compare pre-secondary with secondary care 
delay. The median primary care delay of 15 days is comparable to the recent National 
Audit33 and our 2-week and 31-day waits well within target.  An early interview-based study 
of pre-secondary care delay found a median of 32.5 days, but possibly early symptoms were 
missed21.  The same study found that non-respiratory symptoms were associated with 
longer delay, but we have not found this 21.
Of the causes of delay patients gave, delay and anxiety are the most significant. However 
symptom non-recognition23 and smoking are more common. Patients in denial may not 
recognise, or admit to recognising, their symptoms, and those with anxiety may overlook 























cough or hoarseness over a three-month period sought help, compared with 55% of ex-
/never-smokers48, consistent with our finding that smokers delay longer. Longer pack-years 
of smoking are also associated with longer delay, as is COPD35.
If we combine patients who mentioned symptoms before the date given for the start of the 
illness with the patients who declared symptom non-recognition as causing their delay, this 
shows that almost half our patients (46.7%) showed symptom non-recognition.  In a recent 
UK population study, 38% of people could not recall any lung cancer symptoms43. By 
contrast, international studies reported this percentage as 11.5%49 to 17%50. 
Within-patient delay and survival
Within-patient delay is the longest phase, yet we saw no relationship between this and 
survival. Also, metastatic symptoms were not associated with delay (Supplementary Table 
4), suggesting that a significant number of patient develop metastases early. In fact of 91 
(24%) patients with metastatic symptoms, 34 (37.4%) developed these within three months 
of their first symptom. 
After patients who developed metastatic symptoms within three months are excluded, in 
the remaining patients, those with a within-patient delay of 6-12 months had worse survival 
than those with short delay (Supplementary Table 6). 
This suggests that two processes operate in lung cancer, both likely to worsen survival:  
metastases, which may occur early, and unpredictably, in lung cancer, and delay to 
treatment. This analysis would need to be repeated in larger series. However, this factor, 
the proportion of patients who develop early metastases, may explain contradictory 























Implications for research and practice 
Since most delay occurs before any contact with primary care, this phase especially needs to 
be targeted. Action is needed in three areas: public health, primary care networks and 
practices.
Symptom non-recognition remains common, therefore increased awareness campaigns 
need to continue in public health and primary care networks. Current /ever-smokers are 
identifiable through smoking registers available in primary care51. A network nurse could 
liaise, by phone, text or email, with these at-risk people, ensuring they receive proactive 
education, using self-help manuals52,15, checking for lung cancer symptoms and encouraging 
earlier referral for investigations or to secondary care. This is possible during the current 
Covid-19 crisis, and would require only modest funding.
In addition, every primary care consultation, COPD review or health check in ever-smokers 
can be used for opportunistic questioning regarding lung cancer awareness and relevant 
symptoms.
We plan to report separately our study of symptoms in early detection of lung cancer in 
primary care.
ADDITIONAL INFORMATION
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